Abstract
JC virus (JCV) is the causative agent of progressive multifocal leukoenchaphalopathy (PML). The disease develops when JCV gains access to the central nervous system, infects and destroys oligodendrocytes. The disease is rapidly progressing, typically fatal and no effective therapies exist to treat or prevent PML. The recent occurrence of PML in multiple sclerosis patients being treated with Avonex (IFNβ1-a) and Tysabri (Natalizumab) and the recent reports linking JCV infection to the 5HT 2a serotonin receptor led us to evaluate the effects of IFNβ1-a and a panel of 5HT 2a receptor antagonists for their ability to modulate virus infection. IFNβ1-a was found to be a potent inhibitor of both virus infection and viral early and late gene expression. In addition, several 5HT 2a receptor antagonists inhibited initial infection of cells by JCV but were less effective at reducing viral loads in an already established infection.
Accepted Version (
Free)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call